

Thorsten Derlin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6600097/publications.pdf>

Version: 2024-02-01

125
papers

3,300
citations

159585

30
h-index

175258

52
g-index

127
all docs

127
docs citations

127
times ranked

3850
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility of ¹⁸ F-Sodium Fluoride PET/CT for Imaging of Atherosclerotic Plaque. <i>Journal of Nuclear Medicine</i> , 2010, 51, 862-865.	5.0	237
2	Correlation of Inflammation Assessed by ¹⁸ F-FDG PET, Active Mineral Deposition Assessed by ¹⁸ F-Fluoride PET, and Vascular Calcification in Atherosclerotic Plaque: A Dual-Tracer PET/CT Study. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1020-1027.	5.0	175
3	Molecular Imaging of the Chemokine Receptor CXCR4 After Acute Myocardial Infarction. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 1417-1426.	5.3	159
4	In Vivo Imaging of Mineral Deposition in Carotid Plaque Using ¹⁸ F-Sodium Fluoride PET/CT: Correlation with Atherogenic Risk Factors. <i>Journal of Nuclear Medicine</i> , 2011, 52, 362-368.	5.0	157
5	Initial Experience with Volumetric ⁶⁸ Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1962-1968.	5.0	120
6	¹⁸ F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. <i>Theranostics</i> , 2020, 10, 1-16.	10.0	117
7	Clinical Molecular Imaging of Chemokine Receptor CXCR4 Expression in Atherosclerotic Plaque Using ⁶⁸ Ga-Pentixafor PET: Correlation with Cardiovascular Risk Factors and Calcified Plaque Burden. <i>Journal of Nuclear Medicine</i> , 2018, 59, 266-272.	5.0	92
8	Comparative diagnostic performance of ¹⁸ F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation. <i>European Radiology</i> , 2013, 23, 570-578.	4.5	87
9	Comparative Effectiveness of ¹⁸ F-FDG PET/CT Versus Whole-Body MRI for Detection of Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1. <i>Clinical Nuclear Medicine</i> , 2013, 38, e19-e25.	1.3	84
10	⁶⁸ Ga-PSMA I&T PET/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. <i>European Radiology</i> , 2016, 26, 4345-4353.	4.5	73
11	Comparison of standard and delayed imaging to improve the detection rate of [⁶⁸ Ga]PSMA I&T PET/CT in patients with biochemical recurrence or prostate-specific antigen persistence after primary therapy for prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 960-968.	6.4	70
12	Imaging of multiple myeloma: Current concepts. <i>World Journal of Orthopedics</i> , 2014, 5, 272.	1.8	67
13	¹⁸ F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 493-500.	6.4	66
14	An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma. <i>Nature Reviews Urology</i> , 2018, 15, 511-521.	3.8	61
15	Imaging of chemokine receptor CXCR4 expression in culprit and nonculprit coronary atherosclerotic plaque using motion-corrected [⁶⁸ Ga]pentixafor PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1934-1944.	6.4	58
16	⁶⁸ Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 431-439.	2.0	56
17	Patterns of Progression After ⁶⁸ Ga-PSMA-Ligand PET/CT-Guided Radiation Therapy for Recurrent Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 95-104.	0.8	53
18	Molecular imaging-guided repair after acute myocardial infarction by targeting the chemokine receptor CXCR4. <i>European Heart Journal</i> , 2020, 41, 3564-3575.	2.2	52

#	ARTICLE	IF	CITATIONS
19	Multiple Time-Point ⁶⁸ Ga-PSMA I&T PET/CT for Characterization of Primary Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2017, 42, e286-e293.	1.3	49
20	The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2360-2373.	6.4	46
21	⁶⁸ Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2017, 51, 314-322.	1.0	44
22	Feasibility of ¹¹ C-Acetate PET/CT for Imaging of Fatty Acid Synthesis in the Atherosclerotic Vessel Wall. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1848-1854.	5.0	43
23	Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. <i>Radiotherapy and Oncology</i> , 2019, 141, 208-213.	0.6	42
24	PSMA Expression in Tumor Neovasculature Endothelial Cells of Follicular Thyroid Adenoma as Identified by Molecular Imaging Using ⁶⁸ Ga-PSMA Ligand PET/CT. <i>Clinical Nuclear Medicine</i> , 2017, 42, e173-e174.	1.3	39
25	Validation of Automated Perfusion-Weighted Phase-Resolved Functional Lung (PREFUL)-MRI in Patients With Pulmonary Diseases. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 103-114.	3.4	39
26	Integrating MRI and Chemokine Receptor CXCR4-Targeted PET for Detection of Leukocyte Infiltration in Complicated Urinary Tract Infections After Kidney Transplantation. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1831-1837.	5.0	38
27	Cardiac Fibroblast Activation in Patients Early After Acute Myocardial Infarction: Integration with MR Tissue Characterization and Subsequent Functional Outcome. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1415-1423.	5.0	36
28	PSA-stratified detection rates for [⁶⁸ Ga]THP-PSMA, a novel probe for rapid kit-based ⁶⁸ Ga-labeling and PET imaging, in patients with biochemical recurrence after primary therapy for prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 913-922.	6.4	34
29	Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation. <i>European Urology Focus</i> , 2021, 7, 309-316.	3.1	34
30	Differentiation of peripheral nerve sheath tumors in patients with neurofibromatosis type 1 using diffusion-weighted magnetic resonance imaging. <i>Neuro-Oncology</i> , 2019, 21, 508-516.	1.2	32
31	Intraprostatic Tumor Segmentation on PSMA PET Images in Patients with Primary Prostate Cancer with a Convolutional Neural Network. <i>Journal of Nuclear Medicine</i> , 2021, 62, 823-828.	5.0	32
32	Intraindividual Comparison of ¹²³ I-mIBG SPECT/MRI, ¹²³ I-mIBG SPECT/CT, and MRI for the Detection of Adrenal Pheochromocytoma in Patients With Elevated Urine or Plasma Catecholamines. <i>Clinical Nuclear Medicine</i> , 2013, 38, e1-e6.	1.3	27
33	Molecular Imaging in Oncology Using Positron Emission Tomography. <i>Deutsches A&#x0308;rztblatt International</i> , 2018, 115, 175-181.	0.9	27
34	Neuroendocrine Differentiation and Response to PSMA-Targeted Radioligand Therapy in Advanced Metastatic Castration-Resistant Prostate Cancer: A Single-Center Retrospective Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1602-1606.	5.0	25
35	⁶⁸ Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy. <i>Anticancer Research</i> , 2017, 37, 1273-1280.	1.1	25
36	Molecular Imaging of Chemokine Receptor CXCR4 in Non-Small Cell Lung Cancer Using ⁶⁸ Ga-Pentixafor PET/CT. <i>Clinical Nuclear Medicine</i> , 2016, 41, e204-e205.	1.3	24

#	ARTICLE	IF	CITATIONS
37	Quantitation of Perfused Lung Volume Using Hybrid SPECT/CT Allows Refining the Assessment of Lung Perfusion and Estimating Disease Extent in Chronic Thromboembolic Pulmonary Hypertension. <i>Clinical Nuclear Medicine</i> , 2018, 43, e170-e177.	1.3	24
38	Comparison of image quality and visibility of normal and abnormal findings at submillisievert chest CT using filtered back projection, iterative model reconstruction (IMR) and iDose 4. <i>European Journal of Radiology</i> , 2016, 85, 1971-1979.	2.6	23
39	Patterns of relapse as determined by 68Ga-PSMA ligand PET/CT after radical prostatectomy. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 303-310.	2.0	23
40	Advanced imaging in pulmonary hypertension: emerging techniques and applications. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1407-1420.	1.5	23
41	Clinical Molecular Imaging of Pulmonary CXCR4 Expression to Predict Outcome of Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis. <i>Chest</i> , 2021, 159, 1094-1106.	0.8	23
42	Imaging Characteristics and First Experience of [68Ga]THP-PSMA, a Novel Probe for Rapid Kit-Based Ga-68 Labeling and PET Imaging: Comparative Analysis with [68Ga]PSMA I&T. <i>Molecular Imaging and Biology</i> , 2018, 20, 650-658.	2.6	22
43	¹⁸ F-FDG PET/CT in Left-Ventricular Assist Device Infection: Initial Results Supporting the Usefulness of Image-Guided Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 971-976.	5.0	22
44	Molecular imaging of inflammation crosstalk along the cardio-renal axis following acute myocardial infarction. <i>Theranostics</i> , 2021, 11, 7984-7994.	10.0	22
45	Adrenal Epithelioid Angiosarcoma Metastatic to the Epicardium. <i>Clinical Nuclear Medicine</i> , 2012, 37, 914-915.	1.3	21
46	Nerve Sheath Tumors in Neurofibromatosis Type 1: Assessment of Whole-Body Metabolic Tumor Burden Using F-18-FDG PET/CT. <i>PLoS ONE</i> , 2015, 10, e0143305.	2.5	20
47	A randomized, double-blind, crossover comparison of novel continuous bed motion versus traditional bed position whole-body PET/CT imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 711-717.	6.4	20
48	Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers—Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. <i>Journal of Clinical Medicine</i> , 2019, 8, 1060.	2.4	20
49	Influence of short-term dexamethasone on the efficacy of ¹⁷⁷ Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2020, 80, 619-631.	2.3	20
50	Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy. <i>BMC Cancer</i> , 2020, 20, 362.	2.6	20
51	Comparison of 68Ga-PSMA ligand PET/CT versus conventional cross-sectional imaging for target volume delineation for metastasis-directed radiotherapy for metachronous lymph node metastases from prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 420-429.	2.0	19
52	The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1. <i>PLoS ONE</i> , 2020, 15, e0232031.	2.5	18
53	PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under 177Lu-PSMA-617 Radioligand Therapy. <i>Cancers</i> , 2021, 13, 2938.	3.7	18
54	¹⁸ F-FDG PET/CT of off-target lymphoid organs in CD19-targeting chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma. <i>Annals of Nuclear Medicine</i> , 2021, 35, 132-138.	2.2	17

#	ARTICLE	IF	CITATIONS
55	CXCR4-Targeted Imaging of Post-Infarct Myocardial Tissue Inflammation. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 372-374.	5.3	17
56	Detection of occult vertebral fractures by quantitative assessment of bone marrow attenuation values at MDCT. <i>European Journal of Radiology</i> , 2014, 83, 167-172.	2.6	16
57	Assessment of bone marrow inflammation in patients with myelofibrosis: an 18F-fluorodeoxyglucose PET/CT study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 696-705.	6.4	16
58	MDCT of acute pancreatitis: Intraindividual comparison of single-phase versus dual-phase MDCT for initial assessment of acute pancreatitis using different CT scoring systems. <i>European Journal of Radiology</i> , 2016, 85, 2014-2022.	2.6	16
59	Sentinel lymphadenectomy in cervical cancer using near infrared fluorescence from indocyanine green combined with technetium-99m nanocolloid. <i>Lasers in Surgery and Medicine</i> , 2018, 50, 994-1001.	2.1	16
60	Comparison of MRI and VQ-SPECT as a Screening Test for Patients With Suspected CTEPH: CHANGE-MRI Study Design and Rationale. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 51.	2.4	16
61	Value of PET imaging for radiation therapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1-23.	2.0	16
62	99mTc-MDP SPECT/CT for Assessment of Condylar Hyperplasia. <i>Clinical Nuclear Medicine</i> , 2013, 38, e48-e49.	1.3	14
63	Reduced-dose abdominopelvic CT using hybrid iterative reconstruction in suspected left-sided colonic diverticulitis. <i>European Radiology</i> , 2016, 26, 216-224.	4.5	14
64	Volumetric 68Ga-DOTA-TATE PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with metastatic gastroenteropancreatic neuroendocrine tumors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 66, .	0.7	14
65	Magnetic resonance enterography for assessment of intestinal graft-versus-host disease after allogeneic stem cell transplantation. <i>European Radiology</i> , 2015, 25, 1229-1237.	4.5	13
66	Multitracer Molecular Imaging of Paget Disease Targeting Bone Remodeling, Fatty Acid Metabolism, and PSMA Expression on PET/CT. <i>Clinical Nuclear Medicine</i> , 2016, 41, 991-992.	1.3	13
67	Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [68Ga]PSMA-PET-guided metastasis-directed therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2328-2338.	6.4	13
68	Evaluation of ⁶⁸ Ga-Glutamate Carboxypeptidase II Ligand Positron Emission Tomography for Clinical Molecular Imaging of Atherosclerotic Plaque Neovascularization. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2213-2219.	2.4	12
69	Early Detection of Bilateral Testicular Metastases From Prostatic Adenocarcinoma Using 68Ga-PSMA Ligand PET/CT. <i>Clinical Nuclear Medicine</i> , 2017, 42, 563-564.	1.3	12
70	Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy. <i>Diagnostics</i> , 2021, 11, 504.	2.6	12
71	[18F]DCFPyL PET/CT for Imaging of Prostate Cancer. <i>Nuklearmedizin - NuclearMedicine</i> , 2022, 61, 240-246.	0.7	12
72	Quantification of [18F]-FDG uptake in atherosclerotic plaque: impact of renal function. <i>Annals of Nuclear Medicine</i> , 2011, 25, 586-591.	2.2	11

#	ARTICLE	IF	CITATIONS
73	68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Metastasizing Epithelioid Hemangi endothelioma. <i>Clinical Nuclear Medicine</i> , 2017, 42, e478-e479.	1.3	11
74	Assessment of liver ischemia reperfusion injury in mice using hepatic T ₂ mapping: Comparison with histopathology. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 1586-1594.	3.4	11
75	High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT. <i>Journal of Nuclear Medicine</i> , 2021, 62, 514-520.	5.0	11
76	Combining 68Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study. <i>Frontiers in Oncology</i> , 2021, 11, 640467.	2.8	11
77	Abnormal F-18 Fluoride Uptake in Intracranial Meningiomas on PET/CT. <i>Clinical Nuclear Medicine</i> , 2010, 35, 806-807.	1.3	10
78	Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4077-4088.	6.4	10
79	Re: Lars BudÅus, Sami-Ramzi Leyh-Bannurah, Georg Salomon, et al. Initial Experience of 68Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. <i>Eur Urol</i> 2016;69:393â€6. <i>European Urology</i> , 2016, 70, e37-e38.	1.9	9
80	68Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Metastasizing Chordoma. <i>Clinical Nuclear Medicine</i> , 2017, 42, e210-e211.	1.3	9
81	Serial ¹⁸ F-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1556-1559.	5.0	8
82	CXCR4-targeted therapy in breast cancer. <i>Lancet Oncology</i> , The, 2018, 19, e370.	10.7	8
83	Targeting Chemokine Receptor CXCR4 and Translocator Protein for Characterization of High-Risk Plaque in Carotid Stenosis Ex Vivo. <i>Stroke</i> , 2018, 49, 1988-1991.	2.0	8
84	Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 1006-1017.	2.0	8
85	Synchronous Bronchioloalveolar and Squamous Cell Lung Cancer With Different 18F-FDG Avidity on PET/CT. <i>Clinical Nuclear Medicine</i> , 2012, 37, e255-e256.	1.3	7
86	18F-FDG PET/CT for Staging and Detection of Extramedullary Organ Involvement in Chronic Myelomonocytic Leukemia. <i>Clinical Nuclear Medicine</i> , 2014, 39, 811-812.	1.3	7
87	Perfusion Single Photon Emission Computed Tomography in a Mouse Model of Neurofibromatosis Type 1: Towards a Biomarker of Neurologic Deficits. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1304-1312.	4.3	7
88	Gd-EOB-DTPA-enhanced MRI for quantitative assessment of liver organ damage after partial hepatic ischaemia reperfusion injury: correlation with histology and serum biomarkers of liver cell injury. <i>European Radiology</i> , 2018, 28, 4455-4464.	4.5	7
89	Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 664225.	2.8	7
90	F-18 FDG PET/CT Findings of Aggressive NK-Cell Leukemia. <i>Clinical Nuclear Medicine</i> , 2011, 36, 932-933.	1.3	6

#	ARTICLE	IF	CITATIONS
91	Seeing the unseen: post-infarction inflammation in an isolated right ventricular myocardial infarction visualized by combined cardiac magnetic resonance imaging and chemokine receptor CXCR4-targeted molecular imaging. <i>European Heart Journal</i> , 2018, 39, 966-966.	2.2	6
92	High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with ¹⁸ F-DCFPyL. <i>Molecular Imaging</i> , 2022, 2022, 7056983.	1.4	6
93	Incidental findings in cardiac magnetic resonance imaging: superiority of bSSFP over T1w-HASTE for extra-cardiac findings assessment. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 1581-1587.	1.5	5
94	Visualization of Posttraumatic Splenosis on Chemokine Receptor CXCR4-Targeted PET/CT. <i>Clinical Nuclear Medicine</i> , 2017, 42, e317-e318.	1.3	5
95	¹⁸ F-FDG PET for Detection of Primary Tracheobronchial T-/Natural Killerâ€‘Cellâ€‘Derived Posttransplant Lymphoproliferative Disorder After Lung Transplantation. <i>Clinical Nuclear Medicine</i> , 2017, 42, 988-989.	1.3	5
96	Assessment of Î³-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2021, 13, 1516.	3.7	5
97	Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMAâ€‘targeted radioligand therapy. <i>Prostate</i> , 2022, 82, 86-96.	2.3	5
98	Molecular imaging of glutamate-carboxypeptidase II (prostate-specific membrane antigen) in malignant epithelioid hemangioendothelioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1943-1944.	6.4	4
99	⁶⁸ Ga-DOTA-TATE PET/CT for Molecular Imaging of Somatostatin Receptor Expression in Extra-adrenal Paraganglioma in a Case of Complete Carney Triad. <i>Clinical Nuclear Medicine</i> , 2017, 42, e527-e528.	1.3	4
100	Structural alteration of lung parenchyma in patients with NF1: a phenotyping study using multidetector computed tomography (MDCT). <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 29.	2.7	4
101	CD19-Targeted Immunotherapy Attenuates Vessel Wall Inflammation. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1864-1866.	5.3	4
102	MÃ¼nchhausen Syndrome Presenting as Fever of Unknown Origin. <i>Clinical Nuclear Medicine</i> , 2011, 36, 1129-1130.	1.3	3
103	Radiotherapy for isolated lymph node metastases in patients with locally advanced prostate cancer after primary therapy. <i>World Journal of Urology</i> , 2016, 34, 1239-1245.	2.2	3
104	Nonneoplastic Neuroma After Radical Prostatectomy Is Not a Mimicker of Lymph Node Metastases on ⁶⁸ Gaâ€‘PSMA Ligand PET/CT. <i>Clinical Nuclear Medicine</i> , 2016, 41, 785-786.	1.3	3
105	Beta-1-Adrenergic Receptor Antibodies in Acute Coronary Syndrome: Is Less Sometimes More?. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 170.	2.4	3
106	[¹⁷⁷ Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e372.	10.7	3
107	Emerging Molecular Targets for Imaging of Atherosclerotic Plaque using Positron Emission Tomography. <i>Current Radiopharmaceuticals</i> , 2021, 14, 173-183.	0.8	3
108	Diagnostic value of ¹⁸ F-FDG-PET/CT for monitoring myelofibrosis after allogeneic stem cell transplantation. <i>Nuclear Medicine Review</i> , 2015, 18, 35-36.	0.5	3

#	ARTICLE	IF	CITATIONS
109	18F-FDG PET/CT for Detection of Leukemic Transformation in Myelofibrosis. <i>Clinical Nuclear Medicine</i> , 2015, 40, 521-522.	1.3	2
110	Value of 99mTc-Technegas SPECT/CT for Localization of Alveolar-pleural Fistulas. <i>Nuclear Medicine and Molecular Imaging</i> , 2016, 50, 164-165.	1.0	2
111	Prevalence and clinical significance of incidental extra-mammary findings in breast magnetic resonance imaging: A retrospective study of 1070 patients. <i>Clinical Imaging</i> , 2017, 45, 92-95.	1.5	2
112	Extra-vascular findings in patients undergoing magnetic resonance angiography of the abdomen, pelvis and lower extremities: A retrospective study of 352 patients. <i>Vascular</i> , 2018, 26, 27-38.	0.9	2
113	Personalized prediction of mode of cardiac death in heart failure using supervised machine learning in the context of cardiac innervation imaging. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 202-203.	2.1	2
114	Vessel Wall Inflammatory Activity as Determined by F-18 Fluorodeoxyglucose PET in Large Vessel Vasculitis Is Attenuated by Immunomodulatory Drugs. <i>Diagnostics</i> , 2021, 11, 1132.	2.6	2
115	Value of PET imaging for radiation therapy. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 326-343.	0.7	2
116	Glioblastoma Multiforme Metastatic to the Bone. <i>Clinical Nuclear Medicine</i> , 2014, 39, 188-189.	1.3	2
117	Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers. <i>Molecular Imaging and Biology</i> , 2022, , 1.	2.6	2
118	99mTc-Methylene Diphosphonate Bone Scintigraphy Findings in Posttransplant Distal Limb Syndrome. <i>Clinical Nuclear Medicine</i> , 2014, 39, 646-647.	1.3	1
119	Screening of extravascular findings in pulmonary embolism computer tomography: 397 patients with 1950 non-pulmonary artery findings. <i>Vascular</i> , 2018, 26, 99-110.	0.9	1
120	⁶⁸ Ga-PSMA PET/CT imaging predicting intraprostatic tumor extent prior to radical prostatectomy in patients with prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e632-e632.	1.6	1
121	99mTc-HMPAO perfusion SPECT/CT in the diagnosis of brain death. <i>Nuclear Medicine Review</i> , 2016, 19, 22-23.	0.5	1
122	18F-FDG PET/CT for Detection of Metachronous Hodgkin's Disease in Patients with Myelofibrosis. <i>Nuclear Medicine and Molecular Imaging</i> , 2015, 49, 76-77.	1.0	0
123	Re: Sungmin Woo, Chong Hyun Suh, Sang Youn Kim, Jeong Yeon Cho, Seung Hyup Kim. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. <i>Eur Urol</i> . In press. http://dx.doi.org/10.1016/j.eururo.2017.03.042 . <i>European Urology</i> , 2017, 72, e98-e99.	1.9	0
124	Deepening of response to prostate-specific membrane antigen ligand-targeted radioligand therapy beyond end of treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3343-3344.	6.4	0
125	Prostate Cancer Theranostics. , 2021, , 1117-1130.		0